Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.38 |
| ▸ | FABP7 | O15540 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | MDM4 | O15151 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24579267 | 1.00 | CASP3 (0.40) | CASP3NPSR1FABP5FABP7KMT2A | |
| SCHEMBL30054786 | 1.00 | CASP3 (0.40) | CASP3NPSR1FABP5FABP7KMT2A | |
| SCHEMBL29697681 | 1.00 | CASP3 (0.40) | CASP3NPSR1FABP5FABP7KMT2A | |
| SCHEMBL21837756 | 1.00 | CASP3 (0.40) | CASP3NPSR1FABP5FABP7KMT2A | |
| SCHEMBL30522070 | 1.00 | CASP3 (0.40) | CASP3NPSR1FABP5FABP7KMT2A | |
| SCHEMBL24579262 | 0.92 | CASP3 (0.40) | CASP3NPSR1FABP5FABP7KMT2A | |
| SCHEMBL23879137 | 0.92 | CASP3 (0.40) | CASP3NPSR1FABP5FABP7KMT2A | |
| SCHEMBL24579411 | 0.92 | CASP3 (0.40) | CASP3NPSR1FABP5FABP7KMT2A | |
| SCHEMBL31129073 | 0.92 | CASP3 (0.40) | CASP3NPSR1FABP5FABP7KMT2A | |
| SCHEMBL30640796 | 0.92 | CASP3 (0.40) | CASP3NPSR1FABP5FABP7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118354782-A | Compositions comprising peptide compounds for use in combination with surfactants | 中外制药株式会社 | 2024-07-16 | — | — | CN | disclosed |
| CN-118176012-A | Compositions comprising a peptide compound and a surfactant | 中外制药株式会社 | 2024-06-11 | — | — | CN | disclosed |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-16 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| EP-4309741-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-24 | — | — | EP | disclosed |
| EP-4299069-A1 | PREPARATION CONTAINING CYCLIC PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-03 | — | — | EP | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| CN-117279933-A | Cyclic compounds having selective KRAS inhibition relative to HRAS and NRAS | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| WO-2023214576-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | 中外製薬株式会社 | 2023-11-09 | — | — | WO | disclosed |
| US-20220144762-A1 | METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-05-12 | — | — | US | disclosed |
| EP-3939962-A1 | METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-01-19 | — | — | EP | disclosed |
| EP-3896056-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-10-20 | — | — | EP | disclosed |
| EP-3896056-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020122182-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | 中外製薬株式会社 | 2020-06-18 | — | — | WO | disclosed |
| WO-2020122182-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | 中外製薬株式会社 | 2020-06-18 | — | — | WO | disclosed |
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-04-30 | — | — | US | disclosed |
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-04-30 | — | — | US | disclosed |
| EP-3636807-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 2020-04-15 | — | — | EP | disclosed |
| EP-3636807-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 2020-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | KRAS, HRAS, NRAS | CASP3 3300/4885NPSR1 3683/4885FABP5 4703/4885 |
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | VIP, SLC7A1, TRPV1 | CASP3 3512/4885NPSR1 202/4885FABP5 1216/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | CASP3 3268/4885NPSR1 135/4885FABP5 4026/4885 |
| US-20220144762-A1 | METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE | DDC, AADAT, TYR | CASP3 4077/4885NPSR1 2250/4885FABP5 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.